AQR Capital Management LLC acquired a new stake in Grifols, S.A. (NASDAQ:GRFS – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,107 shares of the biotechnology company’s stock, valued at approximately $89,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Cohen Investment Advisors LLC bought a new position in shares of Grifols during the 1st quarter valued at $80,000. Cetera Advisors LLC bought a new position in shares of Grifols during the 1st quarter valued at $147,000. Farallon Capital Management LLC bought a new position in shares of Grifols during the 1st quarter valued at $187,000. Team Hewins LLC lifted its holdings in shares of Grifols by 11.8% during the 1st quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 4,324 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of Grifols during the 1st quarter valued at $316,000.
Grifols Price Performance
NASDAQ GRFS opened at $8.65 on Friday. The business’s fifty day moving average price is $8.58 and its 200-day moving average price is $7.67. The stock has a market capitalization of $5.95 billion, a price-to-earnings ratio of 8.48 and a beta of 0.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15.
Grifols Company Profile
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.
See Also
- Five stocks we like better than Grifols
- What is the Shanghai Stock Exchange Composite Index?
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How to Find Undervalued Stocks
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFS – Free Report).
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.